IP Archives of Cytology and Histopathology Research

Print ISSN: 2581-5725

Online ISSN: 2456-9267

CODEN : IACHCL

IP Archives of Cytology and Histopathology Research (ACHR) open access, peer-reviewed quarterly journal publishing since 2016 and is published under the Khyati Education and Research Foundation (KERF), is registered as a non-profit society (under the society registration act, 1860), Government of India with the vision of various accredited vocational courses in healthcare, education, paramedical, yoga, publication, teaching and research activity, with the aim of faster and better dissemination more...


Article type

Original Article


Article page

274-279


Authors Details

Ravi M Swami, Rachana Lakhe*, Preeti Doshi, Manjiri N Karandikar, Ravindra Nimbargi


Article Metrics


View Article As

 


Downlaod Files

   






Article statistics

Viewed: 77

PDF Downloaded: 43


Immunohistochemical study of ER, PR, p53 and Ki67 expression in patients with endometrial adenocarcinoma and atypical endometrial hyperplasia


Original Article

Author Details : Ravi M Swami, Rachana Lakhe*, Preeti Doshi, Manjiri N Karandikar, Ravindra Nimbargi

Volume : 5, Issue : 4, Year : 2020

Article Page : 274-279

https://doi.org/10.18231/j.achr.2020.060



Suggest article by email

Abstract

Objective: To study Immunohistochemistry pattern of ER, PR, p53 and Ki67 expression in patients with endometrial adenocarcinoma (EC) and endometrial hyperplasia.
Materials and Methods: A retrospective study of 78 cases were studied for a period of 02 year from June 2018 to May 2020, where in the clinical data included age, presenting complaints, menopausal status, history of hormonal treatment, ultrasound examination.
Histopathological parameters were analysed as per WHO 2014 classification of endometrial hyperplasia into typical and atypical endometrial hyperplasia / Endometrial Intraepithelial Neoplasia (EIN) and endometrial carcinoma. ER, PR, p53 and Ki 67 IHC markers were done on cases diagnosed as endometrial adenocarcinoma and endometrial hyperplasia.
Results: Among 78 cases, there were 20 cases of EC and 58 cases of endometrial hyperplasia. EC was most commonly seen in sixth to seventh decade and hyperplasia was seen in fourth to fifth decade .There were 11 surgical specimens and 09 biopsies of EC. Out of total 20 cases, there were 17 cases of endometrioid adenocarcinoma and 03 cases were of papillary serous adenocarcinoma.
ER, PR expression was seen in 10 cases of grade 1 endometrial carcinomas and 5 cases of grade 2 EC. p53 expression was seen in 01 case of grade 1 EC and 03 cases grade 3 EC. ER, PR, p53 all were negative in one case. Ki67 was <10>20% in 04 cases. We followed up 15 out of 20 cases, out of which only 01 patient died of disease who was grade 1 endometrial carcinoma. Rest 14 had progression free survival (PFS) till date. All 58 cases of endometrial hyperplasia were reclassified complex and simple hyperplasia to typical and atypical hyperplasia (as per WHO Classification 2014). Out of 58 cases, 56 cases were typical hyperplasia and 02 cases atypical hyperplasia. ER, PR expression was positive in all the cases of typical and atypical hyperplasia. p53 expression was absent in typical and atypical hyperplasia with low Ki 67 index (<10> Conclusion: High ER, PR expression along with low p53 was seen in type 1 endometrial carcinomas compared to low or absent ER, PR along with strong p53 expression in papillary serous carcinoma (Type 2). The expression of ER, PR was high in typical hyperplasia as against high p53 expression observed in atypical hyperplasia.

Keywords: Endometrial adenocarcinoma, Hyperplasia, Immunohistochemistry.


How to cite : Swami R M, Lakhe R, Doshi P, Karandikar M N, Nimbargi R, Immunohistochemical study of ER, PR, p53 and Ki67 expression in patients with endometrial adenocarcinoma and atypical endometrial hyperplasia. IP Arch Cytol Histopathol Res 2020;5(4):274-279

Copyright © 2020 by author(s) and IP Arch Cytol Histopathol Res. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)